

## Results of election of employee elected members to Zealand's Board of Directors

---

*Copenhagen, 14 April 2016* - Zealand announces that Hanne Heidenheim Bak, Senior Project Director and Rasmus Just, Director of External Sourcing and Research Partnerships have been elected as new employee elected members of Zealand's Board of Directors.

Hanne Heidenheim Bak holds a M.Sc. Pharm. and has been employed at Zealand since 2006.

Rasmus Just holds a PhD and MBA, and has been employed at Zealand since 2003.

Both employee elected members are appointed for a four-year period with effect from Zealand's Annual General Meeting 2016 to be held on 19 April 2016. The two new members will replace Helle Størum and Christian Thorkildsen who both have completed their terms and will resign from the Board with effect also from the Annual General Meeting.

There are in total three employee elected members on Zealand's Board of Directors. Besides the two newly elected members, also Jens Peter Stenvang, Senior Application Specialist is member of the Board. He has also been appointed for a four-year period, however shifted with two years so it runs until Zealand's Annual General Meeting in 2018.

As first and second substitute employee representatives, the following have been elected: Christian Thorkildsen, Project Director and Helle Størum, Director of Business Development.



### For further information, please contact:

**Britt Meelby Jensen**, President and Chief Executive Officer

Tel: +45 51 67 61 28, email: [bmj@zealandpharma.com](mailto:bmj@zealandpharma.com)

**Hanne Leth Hillman**, Senior Vice President, Investor Relations and Communications

Tel: +45 50 60 36 89, email: [hlh@zealandpharma.com](mailto:hlh@zealandpharma.com)

### About Zealand Pharma

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel investigational medicines and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is licensed to Sanofi who markets the product globally (ex-US) as Lyxumia<sup>®</sup> and has it under regulatory review



in the US. The license agreement with Sanofi covers also LixiLan, which is the reference name for the fixed-ratio, single-product combination of lixisenatide and insulin glargine 100 Units/mL (Lantus<sup>®</sup>). LixiLan is under regulatory priority review by the US FDA and regulatory submission in the EU has been planned by Sanofi for Q12016.

Zealand's proprietary pipeline includes: *ZP4207 (single-dose)* for severe hypoglycemia (Phase II); *ZP1848* for Short Bowel Syndrome (Phase II); *ZP4207 (multiple-dose version)* for better hypoglycemia management in diabetes (Phase I); *ZP2929* for diabetes/obesity (Phase I); and several preclinical peptide therapeutics.

The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand's business and activities, please visit: [www.zealandpharma.com](http://www.zealandpharma.com) or follow us on Twitter @ZealandPharma